Drugs approved to treat rheumatoid arthritis block cytokines, the molecules responsible for severe side effects from the immunotherapy, and reduce symptoms in mice.

The immunotherapy eliminated a woman’s metastatic lesions and kept her disease-free for two years.

Sequencing of a single gene can spot patients with a dangerous form of mycosis fungoides better than other prognostic tests.  

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

Mice treated with an immunostimulant had better outcomes when researchers blocked the expression of TNFR2, a compound that helps tumors evade immune attack.

T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections. 

A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro. 

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

At low doses, resveratrol enhanced human T-cell activity in vitro, while at high doses it interfered with cell signaling. 

Researchers continue to identify new T-cell subtypes—and devise ways to use them to fight cancer. The Scientist attempts to catalog them all.